UnitedHealth Ends Spread Pricing, Signals PBM Reform
Optum Rx/UnitedHealth says its ending "spread pricing" in its PBM, after years of criticism, @ShelbyJLiv reports for @endpts This is a big change in PBM policy, as PBMs face pressure to reform some of the practices they've faced scrutiny over: https://t.co/jq4FmvrO9C
Understanding CDC, MAHA: US Public Health Outlook
We're talking CDC, MAHA and what it all means for public health in the US -- today at 11am ET with @WSITYpod + @maxonwifi https://t.co/2ClZf4225D
Early Journalists Should Relocate to DC for Opportunities
Any early career journalist who asks me for advice, I tell them: Move to DC. There's tons of news, many jobs, and more media entrepreneurship and startups than anywhere else, trying to do serious stuff: https://t.co/OGzzcxhNnV
Insurers Reject Medicare Obesity Coverage, Govt Steps In
The insurers didn't want to play ball on Medicare + obesity med coverage, so the govt will pick up the tab. "Balance" program indefinitely delayed, Max reports (after rushing out of the award lunch where he just won for his...
Venrock's Kelonia Bet Yields 45x Return, Potential 100x
Venrock landed a 45x return on Kelonia -- turned $20M into $900M, @ky_lahucik + I learned. Could grow to 100x if the milestones hit. https://t.co/09QgHeDRgw
Merck's $30B Offer Now Exceeds Revolution's Market Cap
Reminder that Merck tried to buy Revolution for $28-$32B (per Jan reporting from FT), vs current market cap after today's great data of $26.5B https://t.co/hoq2P0oiG9
GOP's Vaccine Flip: MAHA's Influence Threatens Republicans
🎙️ Today on Post-Hoc Live at 1230pm: How the GOP flipped on vaccines💉 I'll be talking with former Republican Congressman Dr. @michaelcburgess and our own @maxonwifi. We'll talk about MAHA's takeover of GOP health policy and the risk for Republicans. https://t.co/65bmPKEtHe
Pfizer's Lyme Phase 3 Cut by One‑Third Over Contractor Issues
Pfizer's phase 3 for its Lyme trial was supposed to be 18k patients -- but issues with a contractor at the start of the trial cut the size by a third, and @ky_lahucik + I reported a long time ago...
China's Rise Threatens US Gene Therapy Market
China competition is coming for the US's multimillion-dollar gene therapies -- a must-read from @Jared_Whitlock about what's happening there and how it will affect access around the world: https://t.co/F7KaMv3Kkp